<DOC>
	<DOCNO>NCT02049190</DOCNO>
	<brief_summary>This open-label , randomize , parallel group two-stage phase 1-2 study escalation expansion component . This study evaluate extended-release ( ER ) formulation onapristone patient prostate cancer Progesterone Receptor ( PR ) may contribute tumor progression . A companion diagnostic select patient whose prostate cancer express activate form PR ( APR ) development implement study ; may use enrich selection population base upon ongoing review result . Patients treat occurrence intolerable safety issue , treatment failure , patient elect withdraw , non-compliance either protocol-specified evaluation onapristone treatment . An additional cohort patient include recommended phase 2 dose gain additional understanding onapristone safety profile potential anti-cancer activity .</brief_summary>
	<brief_title>Phase 1-2 Study Onapristone Patients With Advanced Castration-resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Onapristone</mesh_term>
	<criteria>Inclusion criterion : 1 . Male patient , 18 year age great ; 2 . Histologically confirm adenocarcinoma prostate ( without neuroendocrine differentiation small cell feature ) ; 3 . In Stage 2 , mandatory biopsy require confirm PR APR ≥1 % tumor cell . For patient recruit abirateroneonapristone combination arm , biopsy must perform abiraterone administer recent treatment minimum 2 week continuous treatment . For patient , biopsy must take progression abiraterone enzalutamide screen anticancer treatment take intervening period maximum six ( 6 ) month prior study start . If archival tissue also available provide comparison purpose ; pair biopsy day 828 optional ; 4 . Metastatic recurrent inoperable disease previous surgery , radiation therapy , and/or chemotherapy ; 5 . For patient Stage 1 patient Stage 2 receive combination therapy onapristone abiraterone : one prior chemotherapy regimen CRPC ( docetaxel rechallenge regard one line chemotherapy ) ; patient Stage 2 receive onapristone monotherapy : prior chemotherapy allow ; 6 . Disease progress PSA radiologically , abiraterone enzalutamide . Disease progression study entry define one : PSA progression define minimum two rise PSA level interval ≥1 week determination . Radiological progression per RECIST 1.1 ; 7 . For patient recruit abirateroneonapristone combination arm , progression abiraterone last line treatment require prior response abiraterone ; 8 . The PSA value screen baseline ≥ 2 µg/L ( 2 ng/mL ) ; 9 . For onapristone monotherapy , corticosteroid discontinuation &gt; 4 week &gt; 2 week normal adrenal function confirm ACTH stimulation test . For combination onapristone abiraterone arm , prednisolone 5mg BID steroid regimen allow 2 week prior treatment initiation ; 10 . Ongoing androgen deprivation therapy gonadotropin release hormone ( GnRH ) analogue orchiectomy ( i.e. , surgical medical castration ) ; • For patient orchiectomy , must plan maintain effective GnRHanalogue therapy duration trial ; 11 . Serum testosterone level &lt; 1.7 nmol/L ( 50 ng/dL ) ; 12 . Patients receive bisphosphonate therapy must stable dos least 4 week ; 13 . Evaluable disease per RECIST 1.1 [ Eisenhauer 2009 ] Prostate Cancer Clinical Trials Working Group 2 ( PCWG2 ) [ Scher 2008 ] ; 14 . ECOG performance status 02 ; 15 . Life expectancy ≥ 3 month ; 16 . Willing able sign write informed consent per ICHGCP , local regulatory requirement , local data protection law prior studyspecific screen procedure . Exclusion criterion : 1 . Serum creatinine &gt; 1.5 ULN ; 2 . On ECG QTc ( F ) interval &gt; 480 msec clinically significant cardiac rhythm abnormality ; 3 . Liver function test document within screen period and/or baseline : 1 . Total bilirubin &gt; ULN ( except patient diagnose Gilbert 's disease ) ; 2 . Alkaline phosphatase &gt; 2.5 x UNL , unless test alkaline phosphatase isoenzymes elevate bone isoenzyme ; 3 . ALT/AST &gt; UNL &gt; 2.5 x UNL case liver metastasis ; 4 . Absolute neutrophil count &lt; 1,500/µL , platelet count &lt; 100,000/µL , hemoglobin &lt; 5.6 mmol/L ( 9 g/dL ) growth factor blood transfusion within 7 day value ; 5 . Serum albumin &lt; 25 g/L ( 2.5 g/dL ) ; 6 . Known positive virology/serology human immunodeficiency virus ( HIV ) 1 , HIV2 , hepatitis B ( surface antigen ) , hepatitis C ( test require ) ; 7 . Chronic inflammatory liver condition . History clinical evidence liver biliary pathology include cirrhosis , infectious disease , inflammatory condition , steatosis , cholangitis ( include ascend cholangitis , primary sclerosing cholangitis , obstruction , perforation , fistula biliary tract , spasm sphincter Oddi , biliary cyst biliary atresia ; 8 . Patients prior malignancy allow except : 1 . Adequately treat basal cell squamous cell skin cancer ; 2 . Adequately treated Stage I II cancer patient currently complete remission ; 3 . Other cancer patient diseasefree 2 year ; 9 . For Stage 1 : Chronic adrenal failure receive concurrent longterm corticosteroid therapy . Prior longterm corticosteroid must stop ≥4 week &gt; 2 week normal adrenal function confirm ACTH stimulation test prior start study drug ; 10 . History clinical evidence surgical medical condition investigator judge likely interfere result study pose additional risk participating ; e.g. , active clinically significant history disease involve major organ system—vascular , cardiac , uncontrolled hypertension , pulmonary , gastrointestinal , hematologic , neurologic , neoplastic , renal , endocrine immunodeficiency , clinically significant active psychiatric disorder ; 11 . Used prescription medication prior 2 week investigator judge likely interfere study pose additional risk patient participate , specifically inhibitor inducer cytochrome P450 ( CYP ) 3A4 ( see Appendix 4 ) ; 12 . Received investigational product treat investigational device within 30 day prior first drug administration , plan start investigational product device study within 30 day last drug administration ; 13 . Received prior therapy within follow time period prior receipt first dose study drug ( Day 1 , without withdrawal response plan initiate study : 1 . Ketoconazole bicalutamide within 6 week ; 2 . Systemic hormone therapy , chemotherapy , targeted therapy , antibody within 4 week exclude abiraterone abirateroneonapristone combination arm ; 3 . Fractionated radiotherapy within 3 week ; 4 . Single fraction radiotherapy within 2 week ; 5 . Radionuclide therapy within 8 week ; 6 . Brachytherapy Pd103 implant within last 3 month ; 7 . Brachytherapy I125 implant within 12 month . 14 . Concurrent use herbal product may decrease PSA level ( e.g. , saw palmetto ) ; 15 . Residual toxicity prior anticancer treatment &gt; grade 1 except alopecia ; 16 . Brain metastasis , active epidural disease spinal cord compression , unless treat least 4 week entry , stable steroid treatment ≥1 week ; 17 . Paget 's disease bone ; 18 . Structurally unstable bone lesion suggest impending fracture ; 19 . Patients reproductive potential employ adequate contraception treatment 1 month complete treatment ; 20 . Lack physical integrity upper gastrointestinal tract , malabsorption syndrome , inability swallow pill ; 21 . Mental incapacity language barrier preclude adequate understanding , cooperation , compliance study requirement ; 22 . Is , judgment investigator , unable unwilling comply requirement study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Advanced Prostate Cancer</keyword>
	<keyword>Castration-resistant Prostate Cancer</keyword>
	<keyword>Prostatic Neoplasms</keyword>
	<keyword>Genital Neoplasms , Male</keyword>
	<keyword>Urogenital Neoplasms</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Genital Diseases , Male</keyword>
	<keyword>Prostatic Diseases</keyword>
	<keyword>onapristone</keyword>
</DOC>